Explore innovative strategies in coronary interventions, including the EPIC26 sirolimus-eluting stent study, use of percutaneous ventricular assist devices in high-risk patients, the SCORE multicenter study on SeQuent SCB, DCB versus DES for ostial left circumflex lesions, and site-specific antithrombotic therapy outcomes from the DESyne BDS Plus...

Explore the latest insights on risk stratification in NSTEMI patients through comparative analysis of established risk scores such as GRACE, HEART, and TIMI in predicting coronary artery disease severity. This session also reviews outcomes based on diabetes status and left ventricular ejection fraction, prospective validation of...

Prepare for emerging TAVI indications anticipated in 2025. This session reviews clinical cases including asymptomatic severe aortic stenosis, moderate aortic stenosis with heart failure, and severe aortic regurgitation. It discusses supporting evidence from clinical trials, evolving transcatheter technologies, and practical treatment approaches for these novel indications.

This session provides an in-depth evaluation of drug-coated balloons (DCB) as a valid option for coronary revascularisation. Topics include two-year follow-up comparisons between paclitaxel and sirolimus-coated balloons, clinical outcomes after bailout stenting post-DCB angioplasty, meta-analyses contrasting DCB and DES for large native coronary artery disease, and...

Elad Asher reviews the EROSION III trial, presented by Haibo Jia, which studied whether OCT guidance compared with angiographic guidance only is associated with lower stent rate implantation during pPCI in STEMI patients with non-obstructive stenosis.

Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.

It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...

Pierre Deharo and Giuseppe Di Gioia provide their take on this analysis of the 5 years incidence, outcomes and predictors of hemodynamic SVD in patients undergoing TAVI and surgery from the Corevalve US Pivotal and SURTAVI trials.

Nicola Ryan provides her take on the 10-year follow-up of the HOST-EXAM, which was presented by Hyo-Soo Kim at ACC.26 in New Orleans.

Kalaivani Mahadevan provides an in-depth analysis of the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
She also interviewed principal investigators Sarosh Khan and John Davies following the LBCT Scientific Session at ACC.26 in New Orleans and simultaneous publication in...

Ali Nazmi Calik provides a summary and key take-aways and infographics of 9 major trials of interest to interventional cardiologists presented at ACC.21